MergerAug 4, 2026, 04:26 PM
Cyclerion to Merge with Korsana Biosciences; Q2 Net Loss $(1.76)M
AI Summary
Cyclerion Therapeutics announced a merger agreement with Korsana Biosciences, Inc. on April 1, 2026, with the combined entity to be renamed Korsana Biosciences, Inc. The merger, expected to close in Q3 2026, is contingent on stockholder approval and a $380.0 million pre-closing financing by Korsana. Cyclerion's pre-merger shareholders will receive CVRs for legacy assets. The company reported a net loss of $(1.76) million for Q2 2026, with cash and cash equivalents declining to $1.39 million, and noted substantial doubt about its ability to continue as a going concern.
Key Highlights
- Merger Agreement with Korsana Biosciences, Inc. announced on April 1, 2026, expected to close in Q3 2026.
- Cyclerion's pre-merger shareholders will receive Contingent Value Rights (CVRs) for legacy assets.
- Net loss for Q2 2026 was $(1.76) million, compared to $(0.32) million for Q2 2025.
- Cash and cash equivalents decreased to $1.39 million as of June 30, 2026, from $3.24 million at December 31, 2025.
- Total current assets decreased to $1.51 million as of June 30, 2026, from $4.64 million at December 31, 2025.
- Received a $1.0 million milestone payment from Akebia in February 2026 for praliciguat Phase 2 trial initiation.
- Substantial doubt exists regarding the company's ability to continue as a going concern.
- Sold 405,000 shares under an At-the-Market (ATM) offering for $0.8 million net proceeds in January 2026.
Price Impact
More from CYCN